Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic marker for ovarian cancer

A technology of ovarian cancer and markers, which is applied in the field of cancer diagnosis and monitoring, and can solve problems such as diagnosis, grading or prognosis that do not prompt haptoglobin precursors

Inactive Publication Date: 2006-11-29
ROYAL WOMENS HOSPITAL
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] None of the above reports suggest that the detection or measurement of any haptoglobin precursors in biological fluids can be used in the diagnosis, grading or prognosis of ovarian or any other cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic marker for ovarian cancer
  • Diagnostic marker for ovarian cancer
  • Diagnostic marker for ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Example 1 Removal of high-abundance albumin from human serum

[0081] Human serum samples were treated with a mixture of Affinity Gel-Blue and Protein A (5:1) in the form of a spin column (Bio-Rad Laboratories, USA). This spin column contains a mixture of Affinity Gel Blue and Protein A, which selectively binds and removes albumin and immunoglobulins. The spin column was washed twice with 1 ml of binding buffer (20 mM phosphate buffer, pH 7.0) by centrifugation at 1000 xg for 20 seconds. 50 μl of serum was added to 150 μl of binding buffer, mixed by vortexing, and loaded onto a spin column. After incubation for 1 h at room temperature, the column was centrifuged at 1000 x g for 20 sec to collect the eluate. The column was washed with 200 μl binding buffer and the first eluate was combined to generate a discarded serum sample. Determine the total protein concentration of the bound eluate. The eluate was stored at -80°C until further analysis.

[0082] figure 1 a re...

Embodiment 2

[0083] Example 2 Expression of haptoglobin-1 precursor in serum and ascites of patients with ovarian cancer

[0084] Proteomic analysis and mass spectrometry were used to assess the expression of haptoglobin-1 precursor in the serum of normal healthy women and patients with ovarian cancer. Cancer patients were graded according to standard histological methods (Silverberg, 2000).

[0085] The mean ages of the women in the control group and women with ovarian cancer were 47 and 62 years, respectively. Whole blood (10 ml) was collected by venipuncture into flat collection tubes for serum (blood was allowed to clot for 30 minutes at room temperature). Samples were centrifuged at 2000 g for 10 minutes, followed by serum collection. Aliquots (100 [mu]l) were removed for determination of total protein. Serum was stored at -80°C until analysis.

[0086] Serum samples from 8 normal female subjects and 19 ovarian cancer patients were analyzed for haptoglobin-1 precursor expression. ...

Embodiment 3

[0089] Example 3 Serum protein distribution of ovarian cancer patients with different histological grades

[0090] Protein profiles of grade 1 (n=6), grade 2 (n=8) and grade 3 (n=24) ovarian cancer patient sera were analyzed by 2-DE and visualized by staining with SYPRO-Ruby. Using PDQuest software to compare protein profiles from parallel groups of cancer patient samples and normal healthy women (n=8), and Figure 4 shown as a Gaussian distribution. Quantitative evaluation of serum proteins differentially expressed in normal group versus grade 1, 2, or 3 ovarian cancer patients was performed using Student's t-test. Significant differences in the total distribution of serum proteins were obtained in patients with grade 1, 2, and 3 ovarian cancer compared with normal healthy volunteers. Compared with normal serum, 24 proteins were differentially expressed in patients with grade 1 ovarian cancer ( Figure 4 a). Of these proteins, 15 proteins were upregulated 2-fold, 4 protei...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods of detecting, monitoring the efficacy of treatment of, and assessing the severity of ovarian cancer, by assessing the concentration of haptoglobin-1 precursor in a sample of biological fluid. The invention also relates to a kit comprising an antibody or nucleic acid probe specific for haptoglobin-1 precursor for use in the diagnosis of ovarian cancer, monitoring the efficacy of treatment of ovarian cancer, or assessing the severity of ovarian cancer.

Description

[0001] This application claims priority to Australian Provisional Application No. 2003904844, filed 5 September 2003. field of invention [0002] The present invention relates to methods of diagnosis and monitoring of cancer. In particular the present invention relates to methods for the screening of ovarian cancer and other cancers of the reproductive organs, especially in the early stages of the disease, and for the monitoring and prognosis of treatment and clinical management of ovarian cancer and other cancers, and molecular markers for use in said methods. Background of the invention [0003] All references cited in this specification, including any patents or patent applications, are hereby incorporated by reference. No admission is made that any reference constitutes prior art. The discussion of the references states what their authors assert, and the applicants reserve the right to comment on the accuracy and pertinence of the cited documents. It is to be expressly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68G01N33/574G01N33/53
CPCG01N33/57449G01N2800/52
Inventor N·阿梅德G·E·赖斯M·A·奎因
Owner ROYAL WOMENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com